SciVision Biotech Inc (1786) — Cash Flow Quality Index
SciVision Biotech Inc (1786) has a Cash Flow Quality Index of -0.21x as of December 2025. Operating cash flow of NT$-13.02 Million is below net income of NT$63.18 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore 1786 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
SciVision Biotech Inc Cash Flow Quality Index (2011–2025)
Historical Cash Flow Quality Index for SciVision Biotech Inc across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check SciVision Biotech Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for SciVision Biotech Inc (2011–2025)
Year-by-year earnings quality comparison for SciVision Biotech Inc. For live market cap and the full company financial profile, see 1786 market cap.
| Year | Quality Index | Operating CF (TWD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.76x | NT$123.99 Million | NT$162.34 Million | ▼ -31.4% |
| 2024 | 1.11x | NT$269.87 Million | NT$242.25 Million | ▼ -27.1% |
| 2023 | 1.53x | NT$272.01 Million | NT$177.90 Million | ▲ +48.9% |
| 2022 | 1.03x | NT$178.21 Million | NT$173.55 Million | ▲ +21.0% |
| 2021 | 0.85x | NT$98.51 Million | NT$116.06 Million | ▲ +2.3% |
| 2020 | 0.83x | NT$126.47 Million | NT$152.49 Million | ▼ -45.5% |
| 2019 | 1.52x | NT$204.40 Million | NT$134.28 Million | ▲ +26.9% |
| 2018 | 1.20x | NT$111.70 Million | NT$93.10 Million | ▲ +70.2% |
| 2017 | 0.70x | NT$15.98 Million | NT$22.67 Million | ▼ -33.8% |
| 2015 | 1.06x | NT$49.81 Million | NT$46.77 Million | ▼ -10.4% |
| 2013 | 1.19x | NT$37.27 Million | NT$31.36 Million | ▲ +44.0% |
| 2012 | 0.83x | NT$51.52 Million | NT$62.43 Million | ▲ +13.7% |
| 2011 | 0.73x | NT$37.13 Million | NT$51.16 Million | — |